Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10969036 | Vaccine | 2011 | 8 Pages |
Abstract
VAX102 was safe and induced high antibody levels to M2e at 0.3 and 1.0 μg doses. The TLR5 ligand, S. typhimurium flagellin, is a novel approach to adjuvant-like activity through activation of innate immunity, and when fused to multiple copies of the M2e protein, the vaccine was able to induce a fourfold rise in antibody in humans, to a previously non-immunogenic, highly-conserved portion of the influenza virus. Clinical correlates of protection that may be afforded by M2e antibody in humans are a future focus of investigation.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Christine B. Turley, Richard E. Rupp, Casey Johnson, David N. Taylor, Julie Wolfson, Lynda Tussey, Uma Kavita, Lawrence Stanberry, Alan Shaw,